Microbot Medical Inc 2026年季度报告

Form 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2026 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC.(Name of Registrant in Its Charter) Delaware94-3078125State or Other Jurisdiction ofIncorporation or Organization)(I.R.S. EmployerIdentification No.) 175 Derby St., Bld. 27Hingham, MA 02043(Address of principal executive offices) (781) 875-3605(Registrant’s Telephone Number, Including Area Code) (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter periodthat the registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smallerreporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:67,164,801 shares of Common Stock, $0.01 par value at May 13, 2026. MICROBOT MEDICAL INC. AND SUBSIDIARY Index Part I - Financial InformationItem 1 - Financial StatementsInterim Condensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025 (Audited)1Interim Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2026 and2025 (Unaudited)2Interim Condensed Consolidated Statements of Shareholders’ Equity for the Three Months Ended March 31, 2026 and2025 (Unaudited)3Interim Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025(Unaudited)4Notes to Interim Unaudited Condensed Consolidated Financial Statements5Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3 - Quantitative and Qualitative Disclosures About Market Risk26Item 4 - Controls and Procedures26Part II - Other InformationItem 1 - Legal Proceedings27Item 1A - Risk Factors27Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds27Item 3 - Defaults Upon Senior Securities27Item 4 - Mine Safety Disclosures27Item 5 - Other Information27Item 6 - Exhibits27Signatures29 MICROBOT MEDICAL INC. Interim Condensed Consolidated Balance SheetsU.S. dollars in thousands (Except share and per share data) MICROBOT MEDICAL INC. Interim Condensed Consolidated Statements of Comprehensive LossU.S. dollars in thousands (Except share and per share data) MICROBOT MEDICAL INC. Interim Condensed Consolidated Statements of Shareholders’ EquityU.S. dollars in thousands (Except share and per share data) The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. MICROBOT MEDICAL INC. Interim Condensed Consolidated Statements of Cash FlowsU.S. dollars in thousands MICROBOT MEDICAL INC. Notes to Interim Unaudited Condensed Consolidated Financial StatementsU.S. dollars in thousands (Except share and per share data) NOTE 1 – GENERAL A. Description of business Microbot Medical Inc. (the “Company”) is a medical device company specializing in the research, design and development of nextgeneration robotic endoluminal surgery devices targeting the minimally invasive surgery space. The Company is primarily focused onleveraging its robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients. Using the Company’s LIBERTY®technological platform, the Company has developed the first-ever fully disposable robot for variousendovascular interventional procedures. The LIBERTY®Endovascular Robotic System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It is intended for the remote delivery and manipulation